This session provides a timely overview of key Drug Enforcement Administration (DEA) regulatory developments heading into 2026, with a focus on issues directly impacting pharmacy operations and compliance. Attendees will explore DEA’s evolving regulatory agenda, including proposed and final rules issued during 2025, and how federal policy shifts—such as executive orders and regulatory freeze actions—may influence pending regulations. Speakers will break down the latest on telemedicine, including extensions of flexibilities through December 31, 2026, the status of DEA’s proposed special registration framework, and the added burdens these rules could create for dispensing pharmacies. The session will also examine marijuana rescheduling proceedings, potential implications of Schedule III placement, and what rescheduling could mean for pharmacy practice and corresponding responsibility obligations. Finally, the presentation reviews current DEA enforcement priorities, including continued emphasis on “red flags.”